HUNTINGTON BEACH, California, and AMSTERDAM, The Netherlands, March 11 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia and the Netherlands Cancer Institute will present data from multiple studies at the 2009 St.Gallen Breast Cancer Conference. The St. Gallen Breast Cancer Conference, one of the premiere conferences in breast cancer research worldwide, takes place March 11th-14th, 2009 in St.Gallen, Switzerland.
The study results further underpin the predictive and prognostic power of Agendia's breast cancer recurrence test, MammaPrint(R) and will be discussed at the following poster sessions:
Thursday, 12 March 2009
Poster 0063
Comparison of MammaPrint and TargetPrint Results with Clinical Parameters in German Patients (PATH) with Early Stage Breast Cancer
G. Kunz, T. Dimpfl, C. Jakisch, R. Buttner, F. A. de Snoo, O. Krijgsman, E. van Lienen, A. Glas, and R. Bender.
Thursday, 12 March 2009
Poster 0071
The 70 Gene-MammaPrint Profile Allows to Identify a Subgroup of Good-Prognostic Patients with Primary Breast Cancer and 4-9 Positive Lymph Nodes
M. Saghatchian, S. Mook, G. Pruneri, G. Viale, A. Glas, I. Eekhout, M. Knauer, and LJ van 't Veer.
Thursday, 12 March 2009
Poster 0072
The 70-gene MammaPrint Prognosis Signature for Optimal Risk Stratification in Endocrine Responsive Breast Cancer
M Knauer, EJT Rutgers, S Mook, F Cardoso, MJ van de Vijver, G Viale, AM Glas, M. Saghatchian, M Kok, JM Bueno-de-Mesquita, SC Linn and LJ van 't Veer.
Thursday, 12 March 2009
Poster 0073
The 70-gene MammaPrint Signature Is Predictive for Chemotherapy Benefit in Early Breast Cancer
M Knauer, ME Sraver, EJT Rutgers, RA Bender, F Cardoso, S Mook, MJ van de Vijver, M. Saghatchian, RHT Koornstra, JM Bueno-de-Mesquita, S Rodenhuis, SC Linn and LJ van 't Veer.
Thursday, 12 March 2009
Poster 0074
Early Prognosis Prediction: MammaPrint on Core-needle biopsies
F. de Snoo, A. Glas, A. Floore, J. Mayordomo, A. Modollel, C. Rolfo, LJ van 't Veer, E. Rutgers, S. Rodenhuis, and R. Bender.
Thursday, 12 March 2009
Poster 0075
Use of the Genomic Test MammaPrint in Daily Clinical Practice to Assist in Risk Stratification of Young Breast Cancer Patients
G. Kunz, A. Glas and F. de Snoo, I. Simon.
About MammaPrint(R)
MammaPrint is the first 'in vitro diagnostic multivariate index assay' (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-those patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test result provides a doctor with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.
All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.
About Agendia
Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer treatments. The company markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.
Media Contacts: Hans Herklots, Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile, hans.herklots@agendia.com. Valerie Delva, Ricochet Public Relations, +1-212-679-3300 x131 Office, +1-917-975-3191 Mobile, vdelva@ricochetpr.com
Comments